ERBB2 and neoplasm: 111In-labelled bsRICs were less effective than 177Lu-labelled bsRICs for treatment of MDA-MB-231/H2N tumours in mice that co-express HER2 and EGFR, but in this study, the same amount of radioactivity was administered for both bsRICs (11.1 MBq; 10 μg).